Skip to main content

Table 1 Baseline characteristics of the patients included in study (n = 437)

From: Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

Variable

N = 437

Sex

 

   Male (n(%))

239 (54.7)

   Female (n(%))

198 (45.3)

Age (years)*

54.7 ± 12.1

Body mass index (kg/m2)

28.8 ± 4.6

Diabetes (n(%))

125 (28.7)

Fasting plasma glucose (mM/l)*

5.2 ± 0.6

Family history of dyslipidemia (n(%))

171 (39.2)

Coronary heart disease (n(%))

196 (45)

Aspartate aminotranferase (mU/l)

23 ± 11

Alanine aminotransferase (mU/l)

26 ± 14

  1. Data expressed as mean ± standard deviation. *To convert to mg/dl, multiply by 18
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840